MSB 3.21% $1.13 mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-106

  1. 2,888 Posts.
    lightbulb Created with Sketch. 2044
    Yep ten million spent on potency data assays is smoke and mirrors

    FDA not questioning efficacy in the CRL is sorcery

    But you do hope it is approved

    Reg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.